Allergic contact dermatitis is the quintessential example of a delayed-in-time and T-cellYmediated immune response. In the last decade, many of the molecular events required to initiate (or block) such a response have been uncovered. Textbook and journal reviews have emphasized the costimulatory requirements, with less focus on the coinhibitory signals that are of equal importance in understanding this central event of adaptive immunity. To fill this gap, we offer a compendium of discoveries characterizing the ligand-receptor pairs inhibiting T-cell activation and of selected illnesses and therapeutic applications that illuminate their role in health and disease.
A DAPTIVE IMMUNITY begins when antigen (Ag) is presented by dendritic Ag-presenting cells (DCs/APCs) to naive T cells that become activated into memory/effector T cells. The immune response is propagated by subsequent similar interactions between DCs or other APCs (such as B cells and macrophages) with the previously generated and expanding population of memory/effector T cells.
Antigen-presenting cells regulate T-cell activation via 2 concomitant signals. The first involves ligation of Ag bound by major histocompatibility complex (MHC) molecules to the T-cell receptor onT cells. The second is a composite of positive (costimulatory) and negative (coinhibitory) transductions mediated by binding of APC ligands to other receptors on T cells. The combined effect of the 2 signals determines whether Tcells are activated (to proliferate and secrete cytokines) or inhibited (leading to anergy or apoptotic death) (Fig. 1 ). Most recently, some immunologists have referred to a third signal consisting of cytokines that can even rescue partially activated or even anergic T cells. 1 The predominant costimulatory signal results from binding of CD28 on T cells to B7 molecules on APCs. 2, 3 By contrast, several pairs of coinhibitory receptors and ligands have been identified (Tables 1  3Y9 and 2) . Their discovery and relevance to disease states and treatments are the focus of this review.
DISCOVERY AND CHARACTERIZATION OF RECEPTOR-LIGAND PAIRS OF T-CELL INHIBITORS
Over the last 2 decades, T-cell inhibitor pairs have been identified and characterized including cytotoxic T-lymphocyte Ag-4 (CTLA-4) and B7 molecules CD80/CD86; programmed death 1 (PD-1) and ligands PD-L1 and PD-L2; T-cell immunoglobulin (Ig) domain and mucin domain 3 (TIM-3) and galectin 9; B-and T-lymphocyte attenuator (BTLA) and herpesvirus entry mediator (HVEM); and syndecan 4 (SD-4) and DC-associated heparan sulfate proteoglycan-integrin ligand (DC-HIL) ( Tables 1 and 2 ). Almost all of these pairs consist of Ig superfamily molecules on T cells and B7 family members on APCs. The exceptions are HVEM (which belongs to the tumor necrosis factor [TNF] family) and SD-4 and DC-HIL (which are structurally unrelated to the others).
CTLA-4 and B7 Ligands
& CTLA-4 has sequence and structural homology to the costimulator molecule CD28. & CD28 and CTLA-4 bind the same B7 ligands, but the latter does so with higher affinity. & CTLA-4 deficiency in gene-targeted mice causes a severe and fatal T-cell lymphoproliferative disease. Cytotoxic T-lymphocyte Ag-4 was identified through subtractive cloning of a cytotoxic T-cellYderived cDNA library. 10 Its sequence and structural homology to CD28 and ability to bind B7 led investigators to think it was similar to CD28. 11, 12 However, anti-CTLA-4 antibody (Ab) increased proliferation of activated T cells, prompting the conclusion that CTLA-4 transmits an inhibitory signal. 13, 14 Moreover,CTLA-4 j/j mice developed severe and fatal T-cell lymphoproliferative disease, further supporting the concept of CTLA-4 as a T-cell coinhibitor. 15 Unlike CD28, which is expressed constitutively, CTLA-4 is expressed only by activated T cells. Whereas both CD28 and CTLA-4 bind B7-1 and B7-2, CTLA-4 has far greater affinity for both B7 molecules. 12 Following CD28-mediated activation of T cells, CTLA-4 subsequently competes with CD28 for B7 as a coinhibitor of T-cell activation.
PD-1 and PD Ligands (PD-L1 and PD-L2)
& PD-1Ydeficient mice develop a less severe and more gradual autoimmune phenotype than CTLA-4Ydeficient mice. & PD-1 has 2 ligands, PD-L1 and PD-L2.
Programmed death 1 was characterized through subtractive hybridization to search for genes that induce programmed cell death. 16 Like CTLA-4, PD-1 is expressed specifically by activated T cells. However, initially the role of PDs-1 in cell death was unclear because it bears structural similarities to both costimulators (CD28 and ICOS) and coinhibitor (CTLA-4).Whereas CTLA-4 j/j mice develop severe and fatal T-cell lymphoproliferative disease, 15 Programmed death 1 j/j mice develop a slow-progressing lupuslike autoimmune phenotype. 17, 18 Based on homology to other Ig superfamily members, the ligand for PD-1 was thought to belong to the B7 family. That ligand, PD-L1 (B7-H1), is coexpressed with B7-1 and B7-2 molecules on APCs.
19 PD-L1 inhibits T-cell proliferation in wild-type mice but has no impact on PD-1 j/j mice, indicating that PD-L1 inhibits T-cell receptor stimulation. 19 A second ligand, PD-L2 (B7-DC), was also found to antagonize CD28-B7 signaling.
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BTLA and HVEM
& BTLA and HVEM represent the first known interaction between members of the Ig (BTLA) and TNF (HVEM) superfamilies. & BTLA-deficient mice are susceptible to autoimmune disease resembling the PD-1Ydeficient phenotype (but unlike the fatal disease in CTLA-4Ydeficient mice). 
TIM-3 and Galectin 9
& The negative regulatory role of TIM-3 has been studied best in animal models of EAE and autoimmune diabetes. TIM-3 first came to attention as a surface marker specific for differentiated T H 1 cells but was also found on T H 17 cells. 7, 8 Its role in autoimmunity became apparent when blockade of TIM-3 exacerbated EAE in mice and elevated macrophage levels. 26 It also accelerated onset of diabetes in nonobese diabetic mice. 27 Using a soluble TIM-3 Ig fusion protein, researchers demonstrated CD4 + CD25
+ regulatory T cells (Tregs) to express a TIM-3L on their surface after stimulation, whereas the same was not true of CD4 + CD25 j T cells. 27 This implicated Tregs as mediators of the inhibitory effect of TIM-3, as was shown for CTLA-4 and PD-1. Further evidence for the inhibitory role of TIM-3 stems from observations that TIM-3 Ig administration promotes T H 1 proliferation and cytokine release, with reduced T H 1-mediated tolerance. 7 Using TIM-3L Ig fusion proteins, researchers identified galectin 9 as the TIM-3 ligand. 29 In addition to heparin-binding and integrin-recognition motifs (RGD) in the extracellular domain, DC-HIL has an Ig-like domain that suggested a role for DC-HIL in cell-cell interactions.
29,30
Given the constitutive expression of DC-HIL on APCs, investigators envisioned DC-HIL to play a role in activating T cells. However, a recombinant form of DC-HIL (DC-HIL-Fc) preferentially bound already activated (but not resting) Tcells. Moreover, immobilized DC-HIL-Fc that bound to naive (and previously activated) Tcells caused hypoproliferation, evidenced by decreased IL-2 production and cell-cycle arrest.
30 Soluble DC-HIL-Fc, on the other hand, restored T-cell function and promoted T-cell proliferation, most likely by interfering with endogenous DC-HIL binding to its ligand on T cells. 30 Specifically, the Ig-like PKD was critical for DC-HIL's inhibitory function, as PKD-deficient mutant DC-HIL-Fc molecules were unable to elicit T-cell proliferation in response to anti-CD3. 30 Thus DC-HIL is a T-cell inhibitor, and a search for its ligand revealed the heparan sulfate proteoglycan, SD-4.
6 Blocking SD-4 caused decreased binding of DC-HIL to T cells. Knocking down SD-4 led to increased T-cell proliferation. This confirmed SD-4 to be the ligand responsible for the coinhibitory function of DC-HIL. 6 These findings have been supported further by studies in human allogeneic APC/T-cell interactions.
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T-CELL INHIBITORS IN DISEASE AND THERAPEUTICS
The following discussion is categorized into conditions of (1) deficient T-cell inhibition resulting in overactive T cells (causing autoimmune diseases, allergic contact dermatitis [ACD], and organ transplant rejection) and (2) excessive T-cell inhibition resulting in underactive T cells (causing cancers). Nonobese diabetic mice are the animal model for ADM, which can be precipitated by blocking PD-1 and PD-L1. 47 TIM-3 inhibition also precipitated ADM, abrogating tolerance in an islet allograft model treated with donor-specific transfusion and CD40L.
Deficient T-Cell Inhibition Resulting in T-
27 Anti-BTLA Ab eliminated BTLA + B cells and CD4 + T H cells; elevated IL-4, IL-10, IFN-F, and IL-2 production; and enhanced proliferation of Tregs in ADM. 48 Anti-BTLA Ab forestalled disease onset, whereas antiYPD-1 Ab enhanced disease progression. 48 Coadministration of anti-BTLA and antiYPD-1 Ab delayed ADM onset and was associated with reduced pancreatic islet infiltration of B and CD4 + T cells while increasing Tregs. 48 In RA, hyperproliferative synoviocytes lead to pannus formation and the bone destruction that characterizes this autoimmune condition. Galectin 9 seems to be up-regulated in synovial tissue and fluid of RA patients (vs osteoarthritis patients). 49 Fibroblastlike synoviocytes from RA patients were more susceptible to apoptosis when exposed to proteolysis-resistant mutant galectin 9 (vs wild-type galectin 9). 49 In collagen-induced arthritis (CIA, a mouse model for RA), galectin 9 treatment prevented and, in fact, improved CIA. 50 Galectin 9 promoted Treg expression and inhibited T H 17 cells (and therefore IL-17) in inflamed joints of CIA mice. Galectin 9Ydeficient mice more readily acquired CIA with lower levels of splenic Tregs. 50 Thus, it seems that galectin 9 promotes synoviocyte apoptosis and thereby suppresses RA progression.
In psoriasis, reduced activity of CD25 high CTLA-4 + FOXP3
high Tregs is thought to inadequately suppress effector T cells. 51 Galectin 9 limited epidermal thickness and decreased production of IL-17 and IL-22 in an IL-23Yinduced psoriasis mouse model. 52 The higher binding potential of CTLA-4 to B7 molecules 12 has made it a target for dampening costimulatory signals in autoimmune diseases. The CTLA-4 Ig fusion protein abatacept (Orencia) has been used to treat RA. In addition, it is undergoing trials for treatment of moderate to severe ulcerative colitis (clinicaltrials.gov NCT00410410), new-onset type 1 diabetes (clinicaltrials.gov NCT00505375), and MS. 53 The combination of abatacept and cyclophosphamide is being tested for lupus nephritis (ACCESS trial, clinicaltrials.gov NCT00774852).
Allergic Contact Dermatitis
& Allergic contact dermatitis can be prevented by blocking costimulatory signals (eg, using antiYCTLA-4Ab) or by enhancing coinhibitory signals (eg, using galectin 9 mutants or toxinconjugated DC-HIL). & Conversely, ACD is augmented by inhibiting negative signals (eg, using antiYCTLA-4 Ab or using soluble DC-HIL to block SD-4). Allergic contact dermatitis to the hapten 2,4-dinitrofluorobenzene in mice was attenuated by infusion of CTLA-4 Ig, 54 whereas ultraviolet BYinduced tolerance to the same hapten was broken by CTLA-4 blockade. 55 A stable mutant of galectin 9 suppressed ACD in mice manifested by reduced ear swelling with fewer IFN-F and IL-17Yproducing T cells in draining lymph nodes. 52 Infusion of soluble DC-HIL (which prevents binding of DC-HIL to its ligand SD-4 on T cells) during challenge (but not sensitization) produced more robust ACD. 30 This indicates that soluble DC-HIL competes with endogenous DC-HIL for ligation of SD-4 on T cells and thus counteracts its negative signal. In addition, blocking SD-4 through antiYSD-4 Ab or soluble SD-4 receptor also augmented ACD and caused hyperproliferation of T cells in mixed lymphocyte reactions. 6 Only a subset of activated T cells expresses SD-4 (the exclusive ligand of DC-HIL), making it a potentially useful target for therapeutic intervention. Dendritic cellYassociated heparan sulfate proteoglycan-integrin ligand conjugated to a ribosome-inactivating protein, saporin toxin, led to elimination of SD-4 + activated T cells in vitro. 56 By extension, hapten-sensitized mice infused with saporin-bearing DC-HIL before (but not during) hapten challenge experienced markedly less-severe ACD. 56 Such mice have fewer SD-4 + effector memory T cells in both haptenated skin and draining lymph nodes in addition to lower levels of IFN-F, IL-10, and IL-17. BTLA, but not PD-1, mRNA is up-regulated in partially MHCmismatched cardiac allografts and associated with longer survival. 57 However, other studies have demonstrated that allograft rejection leads to elevated PD-1 and PD-L levels. 58, 59 Conversely, allograft rejection was caused by blockade of the BTLA/HVEM pathway and in BTLA j/j mice. 57 Regardless of BTLA and PD-1 expression, fully mismatched allografts were rapidly rejected. 57 In such allografts, PD-1 blockade accelerates rejection, whereas BTLA blockade, surprisingly, enhances PD-1 expression of alloreactive T cells and prolongs graft survival. 57 At low levels of in vitro T-cell activation, BTLA was the main negative regulator expressed. On the other hand, increasing levels of T-cell activation correlated with higher levels of PD-1 expression. 57 These studies demonstrated BTLA to have the dominant role in partial MHC mismatching. PD-L1 Ab treatment of CD28 j/j recipients increased allograft survival 60 mediated by lowered levels of IFN-F and IFN-FY induced chemokines. 58 In a mouse model of graft-versus-host disease, TIM-3 was more highly expressed in hepatic and splenic T cells, DCs, and macrophages. 61 Blocking TIM-3 accelerated graft-versus-host disease. These observations have been extended to fully allogeneic skin grafts 63 and solid organ transplant rejection. Galectin 9 enhanced graft survival and reduced CD4 + and CD8 + T-cell infiltration in a mouse cardiac allograft model. 64 In allograft nephrectomy samples from patients with acute rejection, TIM-3 and galectin 9 mRNA expression patterns correlated with severity of rejection. 65 A number of animal allograft rejection models have demonstrated potential benefits for antiYCTLA-4Ab, paving the way for clinical trials.
66Y68 Belatacept (Nulojix) is a CTLA-4 fusion protein that differs from abatacept by 2 amino acids; it is equivalent in immunosuppressive efficacy to cyclosporine 6 months after renal transplantation from living donors. 69 
Excessive T-Cell Inhibition Resulting in Underactive T Cells
Whereas hyperautoreactive immune responses may cause autoimmunity, ACD, or transplant rejection, an abnormally suppressed immune system allows cancers to proliferate unchecked. Tumor evasion of host immune responses can be mediated by 2 separate mechanisms: (1) enhanced expression of T-cell inhibitors by cancer cells, which down-regulates tumor-specific T-cell activation; or (2) recruitment of Tregs to inhibit naive T cells from maintaining systemic tolerance and thus interfere with the antitumor role of specific Tcells. 70 Regulatory Tcells proliferate at tumor sites, where they inhibit T-cellYmediated cytotoxicity. Elimination of CD4 + CD25
+ Tregs elicits tumor-sensitive CD8 + T cells to eliminate syngeneic tumors in mouse models. This is supported by findings in acute myelogenous leukemia patients, who overexpress Tregs. Syndecan 4 is robustly expressed and susceptible to saporinbearing DC-HIL. 56 Most recently, Chung et al 73 have examined SD-4 expression in the leukemic variant of CTCL, Sezary syndrome. In peripheral blood mononuclear cells isolated from blood samples of patients with Sezary syndrome, SD-4 is constitutively overexpressed by the malignant memory T cells. This was not seen in T cells isolated from patients with atopic dermatitis, psoriasis, mycosis fungoides, or healthy donors. They further demonstrated that overexpressed SD-4 was responsible for inhibiting T-cell activation following ligation to DC-HIL and showed saporin toxin-bound DC-HIL to prevent proliferation of CTCL cells. Patients with unresectable stage III or IV melanoma, who had failed treatment with 1 or more standard chemotherapies, were randomized to ipilimumab alone, gp100 peptide vaccine alone, or combination ipilimumab/gp100. Patients who received ipilimumab (with or without gp100) survived approximately 10 months, compared with 6.4-month survival in those who were given only the gp100 peptide vaccine. 74 However, not surprisingly, a major limitation of ipilimumab treatment has been autoimmune conditions producing dermatitis, hepatitis, and colitis, similar to findings in CTLA-4 knockout mice. 74 Melanoma constitutively expresses high levels of DC-HIL, which may reflect the ability of this cancer to evade adaptive immunity, because DC-HIL inhibits T-cell activation. Investigators tested this hypothesis by generating mouse melanoma cells with knocked-down DC-HIL. While retaining normal phenotype (cell morphology and growth, melanin synthesis, and MHC class I expression), these melanoma cells proliferate at a markedly reduced rate after subcutaneous implantation into immunocompetent mice. 75 The attenuated tumor growth was attributed to greater proliferation of melanoma-specific T cells because of reduced DC-HIL expression. These findings indicate that melanoma can circumvent the immune system through DC-HILYmediated inhibition of tumor-selective T cells and that the DC-HIL/SD-4 pathway is a promising therapeutic target for this malignancy.
Tumor cells evade host immune surveillance by up-regulating PD-L1 (B7-H1), thereby zoffering yet another target for cancer immunomodulation through blockade of either PD-1 or its ligands. 76, 77 Single-agent therapy with the anti-PD1 Ab has been well tolerated in phase 1 trials of patients with advanced metastatic solid and hematologic cancers, including melanoma. 78 Given that CTLA-4 and PD-1 are both negative regulators of T-cell function, studies are in progress to assess the efficacy of dual blockade. In a mouse melanoma model, blockade of CTLA-4 alone led to elimination of 10% of preimplanted tumors. Targeting of both CTLA-4 and PD-1 resulted in 65% rejection of preimplanted tumors with increased effector T cells and cytokine production. 79 
CONCLUSIONS
T-cell inhibitors help orchestrate the complexities of adaptive immunity. Dysregulation can lead to increased T-cell activity, producing autoimmunity, hypersensitivity, and transplant rejection, or reduced tumor-specific T-cell activity producing malignant cell proliferation. Several T-cell inhibitor pairs are being investigated in animal models and clinical trials of TcellYdriven diseases (Table 3) . Two T-cell inhibitorYbased immunomodulators, abatacept (Orencia) and ipilimumab (Yervoy), were FDA approved for RA and metastatic melanoma, respectively. Studies of T-cell inhibitors in ACD, melanoma, psoriasis, and CTCL should soon produce targeted treatment of dermatologic disorders. 
